


Vicore initiates clinical proof-of-concept study of endothelial dysfunction
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO:…

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
12 Abstracts and one Symposium further support potential of ensifentrine,
a…

Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
MOJAVE study on track to start in Q2 2023 as planned, with…

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza
Positive results from testing SPOR-COV in several COVID-19 and…

Curve Therapeutics Expands Leadership Team and Scientific Advisory Board
Dr Monika Ermann appointed Vice President Drug Discovery…

Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Transaction enables Neuraxpharm to further focus on its core…

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting
Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals,…

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology
Boston, Massachusetts, April 26, 2023 - Aldena Therapeutics Inc.…

Massive investment in fundamental cardiometabolic research addresses a growing global public health crisis
Copenhagen-based research center is awarded up to DKK 1 billion…

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference
Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an…

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences in May and June of 2023
Oegstgeest, The Netherlands, 20 April 2023 – ISA Pharmaceuticals,…

Breye Therapeutics Strengthens Management Team and Board
Industry veteran Dr. Peter Adamson, PhD appointed as Chief…

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer
Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG…

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
Ferring Pharmaceuticals and BioInnovation Institute announce…

NeoPhore signs research collaboration with The Institute of Cancer Research, London
London, UK, 18 April 2023, – NeoPhore Limited, a small molecule…

Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
New investors, Andera Partners and Earlybird Venture Capital,…

Futura Medical Announces MED3000, Eroxon® UK Launch
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”),…

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
Expands development of novel GBS vaccine in older adult population…

BioInnovation Institute & Science Prize for Innovation winners announced
BioInnovation Institute (BII), an international non-profit foundation…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York